Apptly Health Completes National Rebrand from UberDoc; Launches Paid Physician and Healthcare Partner Memberships 
How Braden Business Systems Use Auvik SaaS Management
to Identify, Secure, and Manage SaaS Sprawl About Braden Business Systems & Jon Fitzryk Since 1989, Braden Business Systems has...
Efficient Network Management: A Dive into Auvik Network Management’s Robust Features
In today's fast-paced digital world, efficient and effective network management has become more important than ever. With businesses relying heavily...
Apptly Health Completes National Rebrand from UberDoc; Launches Paid Physician and Healthcare Partner Memberships
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (OTCQB: APTHF) (the "Company" or...
Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease
Completion of key IND-enabling activities represents a major development milestone for LB001IND submission remains on track for Q1 2027, followed...
ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics
CORK, Ireland, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, today announced...
Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms
Alethio Therapeutics Rohit Batta, CEO Series A financing co-led by Sofinnova Partners and RA Capital alongside founding investor Oxford Science...
Ethris Reports Positive Topline Phase 2a Data for Nasal mRNA Candidate ETH47 in Asthma Patients Challenged with Rhinovirus
40-fold lower virus load compared to placebo on Day 2, at the peak of viral replicationExposure-response relationship observed, with greater...
9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales...
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments...
Interim report 9M 2026
Strong Q3 sales leading to 9M at 7% organic sales growth and adj. EBITDA margin of 37.9%. 2026 outlook confirmed:...
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
Egetis Therapeutics’ lead asset, EMCITATE®, is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated...
Siemens Healthineers to Rebrand In Vitro Diagnostics Business as Olyrian Diagnostics
Siemens Healthineers announced today it has initiated the carve-out process for its in vitro diagnostics business Olyrian Diagnostics Siemens Healthineers...
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update Ongoing negotiations with different parties towards securing a partnership...
Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2026 Update: Tecan reports acceleration...
IBA signs contract with the Government of Assam for India’s First State-run Proton Therapy Center
The project in Assam marks an important milestone in expanding access to advanced cancer care in India Louvain-La-Neuve, Belgium, November...
Zelluna ASA: Third Quarter 2026 results
Oslo, 5 November 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK)...
Interim Report Q3 2026: Successful product launches leading to 2% organic revenue growth and margin expansion
Highlights The Enterprise division delivered organic revenue growth of 1%, following positive market reception of the second wave of the...
Cloudbreak Pharma Announces Top-Line Results from its Phase 3 Study of CBT-001 in Patients with Pterygium
Both doses of CBT-001 demonstrated statistically significant improvements in conjunctival hyperemia at Month 3 versus vehicle (p Both doses also...
Step Pharma to present data from ongoing phase 2 clinical trial of dencatistat in essential thrombocythaemia at 68th ASH Annual Meeting
First presentation of clinical data from ET programme demonstrating a consistent and clinically meaningful platelet control with favourable tolerability profileVECTRA...
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
TaiMed Biologics to Present 24-Week Phase 2a Data on TMB-365/TMB-380 Maintenance Regimen at HIV Glasgow 2026
Company will present results from a Phase 2a study of TMB-365/TMB-380 administered every eight weeks as maintenance therapy in virologically...
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — — Marks the second...